Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  March 7, 2018

After reviewing a 10-year study, the FDA cautions that prescribing clarithromycin to patients with heart disease increases the risk of heart problems or death…

Filed under:Drug Updates Tagged with:acute painantibioticsApadazclarithromycinHeart Disease

Inside Cambodia’s Struggles with Poverty, Dearth of Trained Rheumatologists

Elizabeth Hofheinz, MPH, Med  |  December 18, 2017

It’s one thing for a developing country to lack physicians due to a scarcity of training. It’s quite another for such a vacuum to exist because the physicians were executed. In Cambodia in the 1970s, genocide perpetrated by the Khmer Rouge spared few of the educated class. If they were spared, chances were they lost…

Filed under:ConditionsProfiles Tagged with:CambodiacostsDiagnosisDr. Victoria SeligmandrugEducationgenocideHealth Volunteers OverseasKhmer RougeLupuspatient carephysicianpovertyrheumatologistrheumatologySihanouk Hospital Center of HopeSLETrainingVolunteer

Upadacitinib Promising for RA in Phase 3 Study

Michele B. Kaufman, PharmD, BCGP  |  December 5, 2017

In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Rheumatoid Arthritis (RA)upadacitinib

European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

Michele B. Kaufman, PharmD, BCGP  |  November 29, 2017

Subcutaneous belimumab has been approved in the EU to help treat patients with active autoantibody-positive SLE…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:belimumabcardiovascularEuropean UnionFebuxostatGoutInternationalsystemic lupus erythematosus (SLE)

futuristman / shutterstock.com

Fulbright Scholar Researches Physical Activity in Swedish Children with Juvenile Idiopathic Arthritis

Carina Stanton  |  October 18, 2017

A stroll through downtown Stockholm presents a quintessential picture of an active community, with most people biking or walking as their preferred mode of travel. Yet children in Sweden who live with juvenile idiopathic arthritis (JIA)—currently estimated at around 64 of every 100,000—don’t always engage in this active lifestyle.1 Maura Daly Iversen, PT, DPT, SD,…

Filed under:ConditionsPediatric ConditionsProfilesResearch Rheum Tagged with:Dr. Maura IversonFulbright ScholarshipJIAJuvenile idiopathic arthritispatient carePediatricphysical activityResearchrheumatologySweden

From the Front Lines: Managing RA Comorbidities in Primary Care

Arthritis Care & Research  |  September 27, 2017

How are comorbidities for RA patients managed outside of rheumatology? A recent Canadian study developed and assessed quality measures related to preventive care and screenings for RA patients in a primary care setting, comparing RA and non-RA patients. The results: Primary care physicians often provide similar levels of care to patients with and without RA. But RA patients were less likely to receive some cancer screenings and all necessary tests to assess their cardiovascular risk…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cardiovascularcomorbiditiespreventiveprimary carePrimary Care PhysicianRheumatoid Arthritis (RA)

When Is a Doctor Too Old to Practice?

Simon M. Helfgott, MD  |  September 18, 2017

Steady hands, nerves of steel: The endoscopic transphenoidal hypophysectomy is a delicate neurosurgical procedure. Using a three-dimensional microscope and a powerful magnetic resonance imaging machine to guide them, the surgeon must meticulously dissect the throat tissues, navigate through the palate and the sinuses to reach the base of the skull where the pea-sized master gland,…

Filed under:OpinionRheuminationsSpeak Out RheumWorkforce Tagged with:agingCareerclinicianpatient carephysicianPractice Managementretirementrheumatologistrheumatologywork-life balance

Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP  |  September 17, 2017

Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:apataceptApprovalsClinicaldrugFDAMedicationOrenciaoutcomePsoriatic ArthritisRAResearchRheumatoid arthritisrheumatologySafetysirukumabstudyTreatmenttrial

Demand for Revision Total Knee Arthroplasty Is on the Rise

Karen Appold  |  September 15, 2017

In the next five to 10 years, the frequency of revision total knee arthroplasty is expected to grow 600%, due to the rise in obesity in the U.S. population and increase in primary knee replacement surgeries. Physicians can use different tools to help decrease the risk of premature implant failure and improve patient outcome…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Hospital for Special Surgerysurgerytotal knee arthroplastytotal knee replacement

Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP  |  August 15, 2017

Citing safety concerns, the FDA Arthritis Advisory Committee voted against recommending approval of sirukumab for treating adults with RA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Drug SafetyFDAFood and Drug AdministrationRheumatoid Arthritis (RA)sirukumab

  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 64
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences